ZA200202293B - Orally distintegrating composition comprising mirtazapine. - Google Patents
Orally distintegrating composition comprising mirtazapine. Download PDFInfo
- Publication number
- ZA200202293B ZA200202293B ZA200202293A ZA200202293A ZA200202293B ZA 200202293 B ZA200202293 B ZA 200202293B ZA 200202293 A ZA200202293 A ZA 200202293A ZA 200202293 A ZA200202293 A ZA 200202293A ZA 200202293 B ZA200202293 B ZA 200202293B
- Authority
- ZA
- South Africa
- Prior art keywords
- mirtazapine
- dosage unit
- orally
- tablets
- unit according
- Prior art date
Links
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims description 63
- 229960001785 mirtazapine Drugs 0.000 title claims description 59
- 239000000203 mixture Substances 0.000 title claims description 20
- 239000013543 active substance Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229920003149 Eudragit® E 100 Polymers 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical group COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000003826 tablet Substances 0.000 description 24
- 239000003814 drug Substances 0.000 description 14
- 239000000935 antidepressant agent Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000001430 anti-depressive effect Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229940023942 remeron Drugs 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006191 orally-disintegrating tablet Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- -1 glidants Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- DEGZUQBZHACZKW-UHFFFAOYSA-N 2-(methylamino)ethyl 2-methylprop-2-enoate Chemical compound CNCCOC(=O)C(C)=C DEGZUQBZHACZKW-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- CLJTZNIHUYFUMR-UHFFFAOYSA-M sodium;hydrogen carbonate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CLJTZNIHUYFUMR-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99203338 | 1999-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200202293B true ZA200202293B (en) | 2003-06-20 |
Family
ID=8240737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200202293A ZA200202293B (en) | 1999-10-13 | 2002-03-20 | Orally distintegrating composition comprising mirtazapine. |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1223914B1 (cs) |
| JP (1) | JP5561885B2 (cs) |
| KR (1) | KR100708560B1 (cs) |
| CN (1) | CN1173701C (cs) |
| AR (1) | AR026010A1 (cs) |
| AT (1) | ATE274899T1 (cs) |
| AU (1) | AU780379B2 (cs) |
| BR (1) | BR0014593A (cs) |
| CA (1) | CA2386547C (cs) |
| CO (1) | CO5251412A1 (cs) |
| CZ (1) | CZ20021315A3 (cs) |
| DE (2) | DE1223914T1 (cs) |
| ES (1) | ES2194618T3 (cs) |
| HK (1) | HK1046641B (cs) |
| HU (1) | HUP0203148A3 (cs) |
| IL (2) | IL148777A0 (cs) |
| MX (1) | MXPA02003519A (cs) |
| NO (1) | NO20021730L (cs) |
| NZ (1) | NZ518165A (cs) |
| PE (1) | PE20010699A1 (cs) |
| PL (1) | PL200858B1 (cs) |
| PT (1) | PT1223914E (cs) |
| RU (1) | RU2261098C2 (cs) |
| SK (1) | SK6452002A3 (cs) |
| TR (1) | TR200200978T2 (cs) |
| TW (1) | TWI256309B (cs) |
| WO (1) | WO2001026621A2 (cs) |
| ZA (1) | ZA200202293B (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2271542T3 (es) * | 2002-02-07 | 2007-04-16 | Pharmacia Corporation | Forma de dosificacion farmaceutica para administracion por la mucosa. |
| US20070298107A1 (en) * | 2003-11-25 | 2007-12-27 | Aurobindo Pharma Ltd. | Pharmaceutical Compositions of Mirtazapine |
| DE102004034043A1 (de) * | 2004-07-13 | 2006-02-09 | Krka Tovarna Zdravil, D.D. | Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält |
| EP2001495A4 (en) * | 2006-02-27 | 2010-12-08 | Alexander Michalow | METHODS OF REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATION |
| CN101129341B (zh) * | 2006-08-22 | 2011-06-01 | 上海医药工业研究院 | 口内崩解组合物及其制备方法 |
| EP2377522B1 (en) | 2010-04-15 | 2013-01-16 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Orally disintegrating tablet formulations of mirtazapine and process for preparing the same |
| CN102993208B (zh) * | 2011-11-22 | 2017-01-18 | 北京哈三联科技股份有限公司 | 去甲肾上腺素和选择性五羟色胺受体阻断剂及其应用 |
| IN2014MN01901A (cs) * | 2012-03-02 | 2015-07-10 | Rhodes Pharmaceuticals Lp | |
| CN104095824B (zh) * | 2013-04-09 | 2016-08-31 | 上海信谊万象药业股份有限公司 | 一种米氮平缓释片及其制备方法 |
| US10603272B2 (en) | 2015-02-27 | 2020-03-31 | Kindred Biosciences, Inc. | Stimulation of appetite and treatment of anorexia in dogs and cats |
| JP6601844B2 (ja) * | 2016-12-05 | 2019-11-06 | 共和薬品工業株式会社 | 光安定性に優れたミルタザピン含有医薬製剤 |
| CN111714463B (zh) * | 2020-08-14 | 2022-06-17 | 华农（肇庆）生物产业技术研究院有限公司 | 米氮平口服剂及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
| US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| EP0494972B1 (en) * | 1989-10-02 | 1996-11-27 | Cima Labs, Inc. | Effervescent dosage form and method of administering same |
| IE63986B1 (en) * | 1989-12-30 | 1995-06-28 | Akzo Nv | Pharmaceutical preparation for oral administration in fluid form |
| JPH0436252A (ja) * | 1990-05-30 | 1992-02-06 | Nippon Alkyl Alum Kk | 光学活性アルキニルアルコールの製造方法 |
| JP3168695B2 (ja) * | 1991-06-14 | 2001-05-21 | 三菱化学株式会社 | ショ糖脂肪酸エステルの置換度の低下方法 |
| US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| JPH05163137A (ja) * | 1991-12-12 | 1993-06-29 | Shin Etsu Chem Co Ltd | 有核顆粒 |
| EP0663897B1 (en) * | 1992-10-07 | 1997-01-29 | Akzo Nobel N.V. | Process for separating enantiomers from a racemic mixture |
| JPH0737473A (ja) * | 1993-07-27 | 1995-02-07 | Murata Mfg Co Ltd | 圧力スイッチ |
| CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| JPH10139659A (ja) * | 1996-09-10 | 1998-05-26 | Freunt Ind Co Ltd | 球形粒子群、その製造方法及びそれを用いた球形粒子製剤 |
| JP3870470B2 (ja) * | 1997-02-07 | 2007-01-17 | 大正製薬株式会社 | マルチプルユニットタイプ徐放性錠剤 |
-
2000
- 2000-09-19 TW TW089119264A patent/TWI256309B/zh not_active IP Right Cessation
- 2000-10-09 CA CA2386547A patent/CA2386547C/en not_active Expired - Fee Related
- 2000-10-09 EP EP00971346A patent/EP1223914B1/en not_active Revoked
- 2000-10-09 AU AU10232/01A patent/AU780379B2/en not_active Expired
- 2000-10-09 CN CNB008142041A patent/CN1173701C/zh not_active Expired - Lifetime
- 2000-10-09 AT AT00971346T patent/ATE274899T1/de active
- 2000-10-09 HK HK02108207.0A patent/HK1046641B/en not_active IP Right Cessation
- 2000-10-09 PT PT00971346T patent/PT1223914E/pt unknown
- 2000-10-09 HU HU0203148A patent/HUP0203148A3/hu unknown
- 2000-10-09 JP JP2001529412A patent/JP5561885B2/ja not_active Expired - Lifetime
- 2000-10-09 SK SK645-2002A patent/SK6452002A3/sk not_active Application Discontinuation
- 2000-10-09 NZ NZ518165A patent/NZ518165A/en not_active IP Right Cessation
- 2000-10-09 ES ES00971346T patent/ES2194618T3/es not_active Expired - Lifetime
- 2000-10-09 BR BR0014593-9A patent/BR0014593A/pt not_active Application Discontinuation
- 2000-10-09 PL PL354584A patent/PL200858B1/pl unknown
- 2000-10-09 CZ CZ20021315A patent/CZ20021315A3/cs unknown
- 2000-10-09 IL IL14877700A patent/IL148777A0/xx unknown
- 2000-10-09 DE DE1223914T patent/DE1223914T1/de active Pending
- 2000-10-09 DE DE60013466T patent/DE60013466T2/de not_active Expired - Lifetime
- 2000-10-09 MX MXPA02003519A patent/MXPA02003519A/es unknown
- 2000-10-09 TR TR2002/00978T patent/TR200200978T2/xx unknown
- 2000-10-09 KR KR1020027004668A patent/KR100708560B1/ko not_active Expired - Lifetime
- 2000-10-09 RU RU2002112238/15A patent/RU2261098C2/ru active
- 2000-10-09 WO PCT/EP2000/009863 patent/WO2001026621A2/en active IP Right Grant
- 2000-10-11 AR ARP000105347A patent/AR026010A1/es not_active Application Discontinuation
- 2000-10-12 CO CO00077918A patent/CO5251412A1/es active IP Right Grant
- 2000-10-13 PE PE2000001100A patent/PE20010699A1/es not_active IP Right Cessation
-
2002
- 2002-03-20 IL IL148777A patent/IL148777A/en not_active IP Right Cessation
- 2002-03-20 ZA ZA200202293A patent/ZA200202293B/en unknown
- 2002-04-12 NO NO20021730A patent/NO20021730L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101020809B1 (ko) | 펙소페나딘을 함유하는 구강 분산성 정제 | |
| US6245353B1 (en) | Solid, rapidly disintegrating cetirizine formulations | |
| US8513439B2 (en) | Antidepressant oral pharmaceutical compositions | |
| US20080176955A1 (en) | Combined administration of benzonatate and guaifenesin | |
| US8455667B2 (en) | Duloxetine compositions in the form of a powder for suspension in a liquid | |
| US20070036861A1 (en) | Orally-dispersible multilayer tablet | |
| EP1223914B1 (en) | Orally distintegrating composition comprising mirtazapine | |
| US20030158265A1 (en) | Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same | |
| CY1653A (en) | Pharmaceutical compositions with analgesic properties and the preparation and use thereof | |
| ZA200600159B (en) | Novel solid pharmaceutical composition comprising amisulpride | |
| JP2004269513A (ja) | 固形製剤 | |
| AU2003224419A1 (en) | Orally administrable pharmaceutical formulation | |
| NZ207768A (en) | Sustained release tablets comprising dipyridamole | |
| US6926906B2 (en) | Orally administrable pharmaceutical formulation | |
| US20210128496A1 (en) | Dropropizine in combination with ambroxol in the dosage form of syrup or tablets |